Todos Medical Ltd. announced that it has entered into a Joint Venture Agreement with Amarantus Bioscience Holdings, Inc. to develop LymPro Test as a diagnostic blood test for Alzheimer disease. LymPro Test is an immune-based neurodiagnostic blood test originally developed at Leipzig University in Germany. Under the terms of the JV Agreement, Todos Medical will issue to Amarantus 19.99% of the outstanding ordinary shares of Todos Medical stock, in exchange for 19.99% of a newly- formed entity called Breakthrough Diagnostics, Inc., with an exclusive option to acquire the remaining 80.01% of Breakthrough Diagnostics in exchange for an additional 30.01% of Todos' shares outstanding.

All rights to LymPro and certain other diagnostic assets will be assigned to Breakthrough Diagnostics, as part of the transaction. Todos Medical's exclusive option will be exercisable upon Amarantus entering into an amended and restated license agreement with the University of Leipzig.